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Abstract
Inspired originally by peptides that traverse biological barriers, research on molecular transporters
has since identified the key structural requirements that govern cellular entry, leading to new,
significantly more effective and more readily available agents. These new drug delivery systems
enable or enhance cellular and tissue uptake, can be targeted, and provide numerous additional
advantages of significance in imaging, diagnostics and therapy.
Introduction
Molecular transporters (MoTrs) are agents that enable or enhance the translocation of drugs
or probes across biological barriers [1,2]. We introduced this term in 2000 to consolidate by
function (i.e., transport) a then growing list of structures and associated names for agents
that affect cellular uptake (e.g., cell penetrating peptides, cell permeating peptides, protein
transduction domains, and membrane translocating peptides), as it was clear from our
studies that the entry of these agents into cells was not a function of their peptide structure
but rather, in the case of the arginine-rich agents, the number and spatial array of their
guanidinium groups [3]. Indeed, in a definitive series of structure-function studies starting in
the 90s and continuing to the present, we have shown that spaced peptide, peptoid,
carbamate, carbonate and dendrimeric scaffolds readily enter cells provided that they are
decorated with the appropriate number and arrangement of guanidinium groups [1]. As is
true of many lessons learned from natural products, the function of these molecular
transporters, in this case translocation into a cell, can thus be mimicked and even improved
upon with alternative simplified structures [4]. We and others have further expanded the
family of transporters, showing that guanidinium-rich (GR) dendrimers, beta-peptides,
foldamers, carbohydrates, PNAs, morpholinos, bicyclic guanidiniums and other non-natural
scaffolds can translocate into cells [1]. GR-molecular transporters (GR-MoTrs) have also
been shown to cross other biological barriers including skin, blood-brain, ocular, buccal, and
membranes of intracellular organelles. Cargoes, which can be either non-covalently
associated with or covalently attached to these molecular transporters, include small
molecules, imaging agents, metals, peptides, proteins, plasmids, and siRNA. Transport of
larger assemblies (e.g., quantum dots, iron particles, vesicles) has also been enhanced by
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guanidinylation [5]. For cases in which free cargo is required to be released after cell entry,
the linker through which the cargo is attached to the transporter can be cleaved by either
abiological methods, including light, pH, and heat, or by biological activation including
protease, esterase, phosphatase, and redox reactions [6]. Significantly, the transporter-cargo
conjugate can be targeted to cells and tissue by “turning off” the oligocation molecular
transporter function through attachment to an oligoanion and then “turning on” uptake by
cleavage of the attached oligoanion using local cellular or tissue biochemistry [7,8].
Molecular transporter technology has progressed to clinical trails initially for the treatment
of psoriasis using cyclosporin-heptaarginine conjugates and subsequently for the treatment
of ischemic damage using RACK peptide-transporter conjugates [9,10]. Significantly, GR-
MoTr drug conjugates have also been shown to overcome multidrug resistant cancer in
cellular and animal models, even when the drug alone succumbs to resistance [6]. Further
therapeutic and research applications of molecular transporters beyond small molecules can
be expected as they provide a solution to the singularly most significant problem associated
with the clinical use of biologics, namely delivery.
Historical Development of Oligoarginine and Guanidinium-Rich Molecular
Transporters
The field of guanidinium-rich molecular transporters (GR-MoTrs) began with the discovery
that the HIV-1 Tat protein crosses cell membranes [11,12], and subsequently that a 9 amino
acid region of this protein (residues 49 to 57: RKKRRQRRR) is responsible for cellular
uptake [13]. The curiously basic nature of this peptide, its high water solubility, and thus its
paradoxical ability to cross the highly nonpolar cellular membrane prompted a detailed
series of structure-function investigations by Rothbard and Wender directed at elucidation of
the requirements for its entry into cells [3]. N- or C-terminal truncated versions of Tat49–57
were found less effective in cellular entry. Similarly, an alanine scan of the Tat 9-mer
peptide showed that deletion of any charged residue resulted in a significant decrease in
cellular uptake. Given the suggested importance of charge, homooligomers of lysine and of
arginine were compared. Oligolysines were ineffective. Strikingly, the arginine
homooligomers significantly outperformed not just other polycations (like lysine oligomers),
but even the original Tat49–57 sequence in uptake (Jurkat cells) [3,14]. Of far reaching
design significance, subsequent studies demonstrated that the unique ability of arginine
oligomers to enter cells was attributable to the number and arrangement of attached
guanidinium groups. Methylation of the guanidinium groups resulted in decreased cellular
uptake, leading to our suggestion that the positively charged guanidinium groups utilize a
bidentate hydrogen bond and electrostatic association to attach to cell surface negatively
charged groups (e.g., phosphates, carboxylates and sulfates) thereby initiating cellular entry
[15]. A visually stunning experiment involving classical partitioning between water and
octanol showed that while fluoresceinated ornithine or arginine homooligomers (both
polycationic) partitioned almost exclusively into the water layer, the addition of sodium
laurate, a membrane fatty acid surrogate, caused the arginine oligomer (but not the
polycationic oligoornithine) to migrate entirely (>95%) into the octanol layer. Thus the
physical properties of this highly polar and water-soluble transporter “morph” from water-
soluble to membrane-soluble upon complexation with membrane lipids. The inwardly
polarized membrane potential is proposed to then drive this complex into the cell. This
mechanism of entry, referred to as adaptive translocation [15], would potentially be
operative for small conjugates with a permissively small cross sectional area. As the size of
the cargo increases, however, competition if not dominance of various endocytotic
mechanisms would arise [16]. In either case, the importance of the guanidinium groups in
complexation remains, as they are also implicated in initiating translocation in other
proposed mechanisms. Finally, it was shown that uptake is not dependent on peptide
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stereochemistry (notably non-natural (D)-oligomers exhibit higher uptake relative to their
(L)-counterparts due to increased protease resistance) further emphasizing the importance of
the guanidinium group as the key feature enabling cell entry [3,14]. The realization that the
number and arrangement of guanidinium groups are the keys for uptake provided a blueprint
for the design of many new peptidic and non-peptidic transporters, opening a field of
opportunities for enabling or enhancing drug and probe delivery (Figure 1).
Applications of GR-MoTrs
As noted above, GR-MoTrs can be used to effect uptake of a long list of probes, drugs and
drug leads. Of particular interest to the theme of this publication, GR-MoTrs are effective
for the delivery of peptides and proteins. Traditionally considered “undruggable” due to
their metabolic instability and general inability to cross biological membranes, many
peptides and proteins can be delivered into cells with MoTr technology. Indeed, an
impressive example of this capability was the early demonstration that an active β-
galactosidase protein could be delivered across the blood-brain barrier in mice by
conjugation to the Tat peptide [17]. More recently oligoarginine-protein fusion constructs
have been used to deliver transcription factors to reprogram somatic cells to induced
pluripotent stem cells [18]. Among the first peptides delivered with oligoarginine
transporters were the RACK octapeptide and Cyclosporine A [9,10]. Both have progressed
into clinical trials.
In addition to the ability to carry classically undruggable cargoes across biological barriers
in cells, animals, and humans, these transporters have been shown to deliver antimicrobials
into parasites without killing the host cell [19]. Molecular transporters can also be designed
to target intracellular organelles such as the nucleus [1] and mitochondria [20]. Many other
groups in addition to those cited herein have creatively contributed to the advancement of
the field over the years including Barton, Bogyo, Bräse, Chung, Cooke, Dervan,
Dmochowski, Dolphin, Kiso, Kumar, Langel, Martinez, Matile, Mendoza, Moulton,
Mueller, Prochiantz, Robbins, Schepartz, Taylor, Torchilin, and Weissledder. Of particular
importance with regards to clinical implementation is the ability to access these GR-MoTrs
with cost-effective, step-economical synthetic strategies. In this regard, GR-homooligomers
offer significant cost and scale advantages in addition to often better performance and
tunability relative to the original Tat-9-mer.
Non-peptidic GR-MoTrs
Linear GR-MoTrs
The first non-peptidic GR-MoTrs were guanidinium-rich oligopeptoids [3]. While retaining
the same 1,4 side chain spacing of the peptide transporters and an amide bond, these peptoid
transporters exhibited more flexibility both along the backbone and between the backbone
and sidechain. Significantly, they worked better than peptides in comparative uptake studies
with Jurkat cells, showing clearly that a conventional peptidic amide bond is not required for
cell entry. That more flexible systems would work better is consistent with the dynamics of
cell entry rather than an affinity based recognition process for which pre-organization would
be important.
Given our finding that the backbone stereochemistry and substitution could be varied,
research was next directed at the effect of backbone spacing and composition on uptake
[21,22,23]. It was found that introduction of aminocaproic acid spacers between arginine
groups resulted in GR-MoTrs that outperformed oligomers of arginine alone [21]. β-
peptides, which contain one additional methylene unit between guanidinium containing side
chains, showed similar behavior to the α-peptide scaffold: the β-oligoarginine performed
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well while the β-oligolysine was less effective [22,24]. An additional and important question
was whether the peptide or peptoid backbone could be more dramatically modified. That
aminocaproic acid spacers between arginines gave better cellular uptake suggested that this
direction would bear fruit. To explore this idea, guanidinium-rich oligocarbamates were
synthesized [23]. These oligocarbamates deviated from peptide scaffolds not only in the way
in which the backbone is joined (via carbamate linkages), but also in the backbone spacing
between guanidinium units (1,6- vs. 1,4-substitution). Guanidinium-rich oligocarbamates
were in fact more effective than oligoarginine (an oligocarbamate 9-mer translocated 2.3
times faster into cells than a 9-mer of D-oligoarginine). Together these studies on linear GR-
MoTrs with modified spacing and backbone composition further underscored the
importance of the number and arrangement of guanidinium groups for uptake.
The polyproline scaffold GR-MoTrs developed by Chmielewski and coworkers are an
interesting “twist” on the above linear scaffolds [25]. The polyproline scaffold adopts a
well-defined left-handed type II helix in polar solvents and can thus be decorated with
hydrophobic leucine groups on one helical face and either hydrophilic guanidinium groups
or ammonium groups on the other. Fluorescienated versions of these polyproline
amphipathic GR-MoTrs were found to penetrate cells effectively, and, as in other studies,
the guanidinium-bearing transporters were found to be more effective than their ammonium-
bearing counterparts. Notably, the most effective of these guanidinium-bearing transporters
outperformed the Tat peptide by almost an order of magnitude. The organization of the
hydrophobic and hydrophilic groups along the backbone was found to be important, as
transporters with scrambled leucine and guanidinium sequences were not as effective as
those organized to form separate hydrophobic and hydrophilic faces. This study
demonstrates that effective transporters go beyond flexible, linear scaffolds and that well
designed three-dimensional GR-MoTr scaffolds can be effective at cellular uptake.
Branched GR-MoTrs
In addition to linear scaffolds, dendrimeric and other branched GR-MoTrs have been shown
to be effective in promoting cellular entry. The first branched scaffolds, synthesized by the
Futaki group in 2002, were based on an amino acid backbone with lysine residues as branch
points [26]. As had been shown for the linear systems, uptake was dependent on the
guanidinium content (number of arginine residues). The groups of Goodman and Harth as
well as our group have reported GR-MoTrs based on dendrimeric scaffolds [27,28,29]. As
with the linear scaffolds, uptake was found to be dependent on the number of guanidinium
groups, with at least six being required for rapid uptake [27]. Shorter oligomers undergo
uptake which, while slow, could still be clinically relevant. In addition to the primary
importance of the guanidinium groups, work by our group on dendrimeric scaffolds has
shown that the scaffold can also play a role in uptake efficiency [29]. In this work different
scaffolds, which had the same number of guanidinium groups but differed in spacing of
these groups along the dendrimeric backbone, were analyzed for cellular uptake.
Significantly, the most effective of these dendrimeric GR-MoTrs outperformed
nonaarginine, while the least flexible dendrimers did not undergo rapid cellular uptake.
Collectively, from a design perspective, these studies indicate that a range of scaffolds, if
properly decorated with guanidinium groups, could be used to achieve cell entry.
Other Scaffolds of GR-MoTrs (Guanidinylation of cargo)
Because of the singular importance of the guanidinium group for cellular uptake and the
flexibility that is allowable in the display of these guanidinium moieties, it follows that
simply guanidinylating a cargo could be used to enhance its cellular uptake. For example,
guanidinylation of oligonucleotides enhances cellular uptake relative to the parent
unguanidinylated scaffold. Guanidinylation strategies for oligonucleotides have included
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peptide nucleic acids with insertion of arginine along the backbone [30], guanidinylation at
the C5 site of a modified deoxyuridine [31], guanidinylation via attachment of an N-alkyl
through the phosphate group of the phosphate backbone [32], and the replacement of the
phosphate group with guanidinium groups along the oligonucleotide backbone [33]. All of
these varied guanidinylation strategies resulted in systems exhibiting enhanced cellular
uptake.
In addition, the guanidinylation of aminoglycosides, including tobramycin and neomycin B,
has proven to be an effective strategy for the enhanced cellular uptake of these
carbohydrates [34,35]. The resulting guanidinoglycosides exhibited sustained or improved
biological function relative to the unmodified scaffold, in one case showing 100 fold greater
inhibition of HIV viral replication by guanidinotobramycin and guanidinoneomycin B [36].
These guanidinoglycosides can also act as GR-MoTrs and have been shown to deliver large
(>300 kDa) bioactive cargoes into cells [37]. Guanidinylated carbohydrate scaffolds based
on inositol and sorbitol have also been shown to readily enter cells [38,39,40]. The sheer
variety of guanidinylation patterns and strategies and the range of cargoes that have been
carried into cells via these strategies highlights the versatility and power of
oligoguanidinylation for enabling or enhancing cellular uptake.
Oligomerization-Based Syntheses of GR-MoTrs
The demonstration that multiple designed linear and branched GR-scaffolds exhibit cell
penetrating ability led next to the investigation of new synthetic methods to assemble GR-
MoTrs that could improve time and step economy and thus lower cost and extend the reach
of this technology to additional applications [4]. Inspired by polymer chemistry, an
oligomerization strategy offers the potential to assemble multiple guanidinium units in a
single operation (Figure 2). This strategy has a number of advantages over traditional
methods of transporter assembly such as solid-phase synthesis, which requires 2 steps for
each added unit or even solution-phase methods such as segment-doubling, which offers a
step count reduction to octaarginine over solid phase synthesis from 17 to 9 steps [41].
Significantly, an oligomerization-based strategy reduces the step count to 2 (oligomerization
and deprotection), but perhaps more importantly, it also allows for flexible and rapid access
to different length transporters without an increase in step count simply by adjusting the
initiator to monomer ratio. For the first time, long as well as short MoTrs can be synthesized
in 2 steps. The flexible nature of this assembly allows for the facile exploration of chemical
space by dialing in additional functional groups with the synthesis of co-oligomers. While
oligomerization-based syntheses give rise to transporters with some polydispersity, the
speed of synthesis and thus the speed with which questions can be addressed offer huge
advantages in addressing cell entry challenges. In addition, polydispersity could be an
advantage in some applications. Significantly, the ability to quickly access new transporters
through oligomerization strategies and to interrogate chemical space could greatly facilitate
basic research and the determination of lead compounds for clinical development.
In 2008, Kiessling and co-workers reported an oligomerization approach to GR-MoTrs with
an alkene backbone using a ring-opening metathesis polymerization (ROMP, Figure 3, a)
[42]. By employing a succinimidyl ester-substituted norbornene monomer and an alkene
initiator containing a ketone, this strategy allowed for post-polymerization incorporation of
both the guanidinium moieties (by displacement of the succinimidyl ester on the side chains)
and a model fluorescent cargo (by reaction with the alkene initiator to form an oxime
linkage). While guanidinylated oligomers of various lengths were synthesized with this
three-step method, initial studies focused on oligomers bearing 10 guanidinium units, which
were shown to effectively enter cells using live-cell microscopy. While both the
guanidinium moieties and the cargo were appended after the oligomerization process, this
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strategy allows for further diversification by appending appropriate reactive functionality to
various monomer side chains, as demonstrated by the ability to construct cell-permeable co-
oligomers displaying a range of functional groups in addition to the required guanidinium
units [43].
In related work by Tew and co-workers, guanidinium-rich oligomers were synthesized by
using ROMP with an oxanorbornene scaffold (Figure 3, b) [44]. Unlike the strategy
described above, the monomer unit contained a protected guanidinium moiety that was
revealed in a simple post-polymerization deprotection step. No cargo (drug or probe) was
attached in these studies, but these guanidinylated oligomers were investigated for their
transport capability and for antimicrobial activity. Interestingly, they were found to have
activity against both gram-positive and gram-negative bacterial strains with low hemolytic
activity against human red blood cells [45]. Both of these guanidinium-rich oligomeric
scaffolds synthesized by ROMP have slightly different properties than peptide-based
systems, namely increased hydrophobicity, which could lead to some differing activity in
biological systems relative to the peptide-based GR-MoTrs.
A final example of guanidinium-rich oligomerization was reported in 2009 by a Stanford-
IBM collaboration utilizing an organocatalytic ring-opening oligomerization process to
access a new class of GR-MoTrs based on a carbonate backbone (Figure 3, c) [46]. These
oligocarbonate GR-MoTrs can be flexibly and efficiently assembled from a cyclic carbonate
monomer containing a protected guanidinium side chain. When a drug or probe is used as
the initiator moiety for the oligomerization, cargo attachment results in the same step as
transporter synthesis. This new family of oligocarbonate GR-MoTrs was shown to enter
cells and deliver cargo analogously to their peptide-based counterparts, using both flow
cytometry and bioluminescence assays. A unique feature of the carbonate backbone
(especially in contrast to the ROMP-synthesized guanidinium oligomers) is their stability
profile; while they exhibit excellent shelf stabilities, they have the novel ability to degrade to
non-toxic products after cellular uptake. This distinguishing feature of the carbonate
backbone, in addition to the synthetic advantages of transporter assembly by a single step
oligomerization strategy, render this scaffold particularly attractive for various biological,
imaging, and therapeutic applications.
Concluding Remarks
In the information-rich age of “omics”, one of the major problems – indeed a grand
challenge, is understanding biological barriers and how to ferry drugs and probes across
those barriers. Nature has provided clues on how this might be done in the form of proteins
like Tat. Guanidinium-rich molecular transporters have taken this inspiration to a new level
in addressing a range of uptake problems. GR-MoTrs allow for the solubilization of many
cargoes while at the same time facilitating passage across nonpolar membranes into cells.
After cell entry they allow cargo “payout” at a rate determined by design and are thus
effectively “molecular controlled release patches”. Oligomerization strategies to synthesize
molecular transporters offer an unprecedentedly quick way to test the benefit of this delivery
technology. Looking forward, the oligomerization approach to molecular transporters
provides the basis for “kits” that would allow rapid cargo conjugation and uptake studies
without the need for lengthy syntheses or special laboratories. Significantly, these
oligomerization strategies allow facile access to diverse chemical space, on a scale that
rivals phage display in terms of the diversity generated when multiple monomers are used.
By virtue of their ability to enable or enhance cellular uptake of many cargo types that were
previously considered undruggable, molecular transporters open for study, imaging and
clinical use, a wider range of compounds including “non-druggable” small molecules,
metals, peptides, proteins, nucleic acids, siRNAs and other biologics.
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Figure 1.
Representative examples of GR-MoTrs.
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Figure 2.
Schematic of synthetic approaches to GR-MoTrs and step count considerations. a) solid-
phase synthesis, b) segment-doubling approach for homooligomers [41], c) oligomerization
approach [46], d) table of step count comparison for the syntheses of different length
oligomeric GR-MoTrs, G = guanidinium containing unit.
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Figure 3.
Syntheses and structures of oligomerization-based GR-MoTrs. a),b) ROMP
oligomerizations [42, 44], c) organocatalytic carbonate oligomerization [46].
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